Literature DB >> 15192453

The gastrointestinal tract and glucose tolerance.

Adrian Vella1, Michael Camilleri, Robert A Rizza.   

Abstract

PURPOSE OF REVIEW: The development of incretin hormones and incretin analogues for the therapy of diabetes highlights the importance of the gastrointestinal tract in the maintenance of glucose tolerance. RECENT
FINDINGS: The review focuses on recent information on the role of incretins and their breakdown products on insulin secretion, gastric emptying, and satiety. The importance of gastric emptying and its absorptive potential as well as of dietary composition on gastric emptying and glucose tolerance is highlighted. The concept of a portal glucose sensor in humans has been the subject of some controversy but has been recently revisited.
SUMMARY: The gastrointestinal tract plays an important part in glucose tolerance. In this review we have examined how factors altering gastric emptying, insulin secretion in response to meal ingestion, and gastric emptying contribute to the maintenance and deterioration of glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192453     DOI: 10.1097/01.mco.0000134375.01310.97

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  13 in total

1.  Pharmacogenetics for type 2 diabetes: practical considerations for study design.

Authors:  Adrian Vella
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

2.  Meal feeding improves oral glucose tolerance in male rats and causes adaptations in postprandial islet hormone secretion that are independent of plasma incretins or glycemia.

Authors:  Torsten P Vahl; Benedikt A Aulinger; Eric P Smith; Deborah L Drazen; Yve Ulrich-Lai; Randy J Seeley; Stephen C Woods; David A D'Alessio
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

Review 3.  The early diagnosis of pancreatic cancer and diabetes: what's the relationship?

Authors:  Changsong Zhang; Guangshun Yang; Yang Ling; Guihua Chen; Tianbao Zhou
Journal:  J Gastrointest Oncol       Date:  2014-12

4.  Chronic parenteral nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal pigs.

Authors:  Barbara Stoll; David A Horst; Liwei Cui; Xiaoyan Chang; Kenneth J Ellis; Darryl L Hadsell; Agus Suryawan; Ashish Kurundkar; Akhil Maheshwari; Teresa A Davis; Douglas G Burrin
Journal:  J Nutr       Date:  2010-10-27       Impact factor: 4.798

5.  Ethnic differences in beta cell adaptation to insulin resistance in obese children and adolescents.

Authors:  R Weiss; J D Dziura; T S Burgert; S E Taksali; W V Tamborlane; S Caprio
Journal:  Diabetologia       Date:  2006-02-03       Impact factor: 10.122

6.  Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.

Authors:  Galina Smushkin; Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

7.  A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.

Authors:  Esi Kittah; Michael Camilleri; Michael D Jensen; Adrian Vella
Journal:  Metab Syndr Relat Disord       Date:  2020-08-20       Impact factor: 1.894

8.  Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers.

Authors:  Gaurav Aggarwal; Pratima Kamada; Suresh T Chari
Journal:  Pancreas       Date:  2013-03       Impact factor: 3.327

Review 9.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Ananda Basu; Gloria M Petersen; Suresh T Chari
Journal:  Lancet Oncol       Date:  2009-01       Impact factor: 41.316

Review 10.  The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery.

Authors:  Kim T Nguyen; Judith Korner
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.